

Clinical trials of B-Raf enzyme inhibitors for melanoma in all type of patients

TrialResults-center www.trialresultscenter.org

1 BRAF inhibitor

Trial	Treatments	Patients	Trials design and methods
vemurafenib vs placebo			
BRIM 8 , 2018 [NCT01667419] n=NA follow-up:	e twice-daily adjuvant oral vemurafenib 960 mg tablets for 52 weeks (1328-day cycles) versus placebo	patients with resected, BRAF V600 mutation-positive melanoma: ICI IIIA (cohort 1) or stage IIIC (cohort 2)	

References

BRIM 8, 2018:

Maio M, Lewis K, Demidov L, Mandal M, Bondarenko I, Ascierto PA, Herbert C, Mackiewicz A, Rutkowski P, Guminski A, Goodman GR, Simmons B, Ye C, Yan Y, Schadendorf D. Adjuvant vemurafenib in resected, BRAF^{V600} mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. *Lancet Oncol* 2018;19:510-520 [29477665]

2 combined BRAF and MEK inhibition

Trial	Treatments	Patients	Trials design and methods
trametinib and dabrafenib vs placebo			
COMBI-AD , 2017 [NCT01682083] n=NA follow-up:	dabrafenib (150 mg twice daily) and trametinib (2 mg once daily) orally for 12 months versus placebo	Patients with completely resected, histologically confirmed, BRAF V600E/K mutation-positive, high-risk [Stage IIIa (lymph node metastasis >1 mm), IIIb or IIIc] cutaneous melanoma	double-blind
trametinib and dabrafenib vs SOC			
COMBI neo , 2018 [NCT02231775] n=NA follow-up:	-	-	
encorafenib plus binimetinib vs vemurafenib			
COLUMBUS , 2018 [NCT01909453] n=192/191 follow-up: 16.6 mo (median)	oral encorafenib 450 mg once daily plus oral binimetinib 45 mg twice daily versus oral vemurafenib 960 mg twice daily	patients with locally advanced unresectable or metastatic melanoma with BRAF V600 mutation	open label 28 countries

References

COMBI-AD, 2017:

Long GV Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. N Engl J Med 2017;377:1813-1823 [28891408] [10.1056/NEJMoa1708539](https://doi.org/10.1056/NEJMoa1708539)

COMBI neo, 2018:

Amaria RN, Prieto PA, Tetzlaff MT, Reuben A, Andrews MC, Ross MI, Glitza IC, Cormier J, Hwu WJ, Tawbi HA, Patel SP, Lee JE, Gershenwald JE, Spencer CN, Gopalakrishnan V, Bassett R, Simpson L, Mouton R, Hudgens CW, Zhao L, Zhu H, Cooper ZA, Wani K, Lazar A Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. Lancet Oncol 2018;19:181-193 [29361468]

COLUMBUS, 2018:

Dummer R Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2018;19:603-615 [29573941] [10.1016/S1470-2045\(18\)30142-6](https://doi.org/10.1016/S1470-2045(18)30142-6)

3 combined BRAF-MEK inhibitors

Trial	Treatments	Patients	Trials design and methods
trametinib and dabrafenib vs dabrafenib			
COMBI-D (Long) , 2014 [NCT01584648] n=423 follow-up:	dabrafenib and trametinib versus dabrafenib monotherapy	previously untreated patients who had unresectable stage IIIC or stage IV melanoma with a BRAF V600E or V600K mutation	
Flaherty , 2012 [NCT01072175] n=162 follow-up:	dabrafenib (150 mg) plus trametinib (1 or 2 mg) versus dabrafenib monotherapy	patients with metastatic melanoma and BRAF V600 mutations	
trametinib and dabrafenib vs vemurafenib			
COMBI-V (Robert) , 2015 [NCT01597908] n=NA follow-up:	-	patients with metastatic melanoma with a BRAF V600 mutation	
vemurafenib and cobimetinib vs vemurafenib			
Larkin , 2014 [NCT01689519] n=NA follow-up:	vemurafenib and cobimetinib versus vemurafenib and placebo	patients with previously untreated unresectable locally advanced or metastatic BRAF V600 mutation-positive melanoma	

References

COMBI-D (Long), 2014:

Long GV Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet 2015;386:444-51 [26037941] [10.1016/S0140-6736\(15\)60898-4](https://doi.org/10.1016/S0140-6736(15)60898-4)

Long GV Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med 2014;371:1877-88 [25265492] [10.1056/NEJMoa1406037](https://doi.org/10.1056/NEJMoa1406037)

Flaherty, 2012:

Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, Hamid O, Schuchter L, Cebon J, Ibrahim N, Kudchadkar R, Burris HA 3rd, Falchook G, Algazi A, Lewis

K, Long GV, Puzanov I, Lebowitz P, Singh A, Little S, Sun P, Allred A, Ouellet D, Kim KB, Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012;367:1694-703 [[23020132](#)]

COMBI-V (Robert), 2015:

Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, Lichinitser M, Dummer R, Grange F, Mortier L, Chiarion-Sileni V, Drucis K, Krajsova I, Hauschild A, Lorigan P, Wolter P, Long GV, Flaherty K, Nathan P, Ribas A, Martin AM, Su Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 2015;372:30-9 [[25399551](#)]

Larkin, 2014:

Larkin J Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med 2014;371:1867-76 [[25265494](#)] [10.1056/NEJMoa1408868](#)

4 About TrialResults-center.org

TrialResults-center is an innovative knowledge database that collects the results of RCTs and provides dynamic interactive systematic reviews and meta-analysis in the field of all major heart and vessels diseases.

The TrialResults-center database provides a unique view of the treatment efficacy based on all data provided directly from clinical trial results, offering a valuable alternative to personal bibliographic search, published meta-analysis, etc. Furthermore, it would allow comparing easily the various concurrent therapeutic for the same clinical condition.

Rigorous meta-analysis method is used to populate TrialResults-center: widespread search of published and non published trials, study selection using pre-specified criteria, data extraction using standard form.

TrialResults-center is continually updated on a weekly basis. We continually search all new results (whatever their publication channel) and these news results are immediately added to the database with a maximum of 1 week.

TrialResults-center is non-profit and self-funded.